MedTrace Logo

Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer

NCT03327662 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-01-06

No results posted yet for this study

Summary

CTC-STOP is a multicentre prospective randomised controlled phase III trial for metastatic castration-resistant prostate cancer patients.

This study will determine if serial CTC counts can be used as early markers of progression to direct early discontinuation of docetaxel chemotherapy in patients with mCRPC without adversely impacting overall survival, when compared with standard approaches to guide treatment switch decisions.

Conditions

  • Adenocarcinoma of the Prostate

Interventions

OTHER

Active CTC Assessment

CTC Counts used to guide treatment switch

Sponsors & Collaborators

  • Prostate Cancer UK

    collaborator OTHER

  • University of Twente

    collaborator OTHER

  • Sanofi

    collaborator INDUSTRY

  • Janssen, LP

    collaborator INDUSTRY

  • Menarini Group

    collaborator INDUSTRY

  • Institute of Cancer Research, United Kingdom

    lead OTHER

Principal Investigators

  • Johann De Bono, MBChB FRCP MSc PhD · Institute of Cancer Research, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-11
Primary Completion
2019-11-30
Completion
2020-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03327662 on ClinicalTrials.gov